Impaired estrogen receptor action in the pathogenesis of the metabolic syndrome

被引:83
|
作者
Hevener, Andrea L. [1 ]
Clegg, Deborah J. [2 ]
Mauvais-Jarvis, Franck [3 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol Diabet & Hypertens, Dept Med,Iris Cantor UCLA Womens Hlth Ctr, Los Angeles, CA 90095 USA
[2] Cedars Sinai Med Ctr, Dept Biomed Sci, Diabet & Obes Res Inst, Los Angeles, CA 90048 USA
[3] Tulane Univ, Endocrinol Sect, Dept Med, Hlth Sci Ctr New Orleans, New Orleans, LA 70112 USA
基金
美国国家卫生研究院;
关键词
Metabolic syndrome; Estrogen action; Insulin resistance; Obesity; ACTIVATED PROTEIN-KINASE; HORMONE REPLACEMENT THERAPY; INDUCED INSULIN-RESISTANCE; CENTRAL-NERVOUS-SYSTEM; BODY-FAT DISTRIBUTION; GLUCOSE-TRANSPORTER GLUT4; CORONARY-HEART-DISEASE; PANCREATIC BETA-CELLS; SKELETAL-MUSCLE CELLS; SEX STEROID-HORMONES;
D O I
10.1016/j.mce.2015.05.020
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Considering the current trends in life expectancy, women in the modern era are challenged with facing menopausal symptoms as well as heightened disease risk associated with increasing adiposity and metabolic dysfunction for up to three decades of life. Treatment strategies to combat metabolic dysfunction and associated pathologies have been hampered by our lack of understanding regarding the biological underpinnings of these clinical conditions and our incomplete understanding of the effects of estrogens and the tissue-specific functions and molecular actions of its receptors. In this review we provide evidence supporting a critical and protective role for the estrogen receptor a specific form in the maintenance of metabolic homeostasis and insulin sensitivity. Studies identifying the ER-regulated pathways required for disease prevention will lay the important foundation for the rational design of targeted therapeutics to improve women's health while limiting complications that have plagued traditional hormone replacement interventions. (C) 2015 Published by Elsevier Ireland Ltd.
引用
收藏
页码:306 / 321
页数:16
相关论文
共 50 条
  • [31] SLE and metabolic syndrome
    Parker, B.
    Bruce, I. N.
    LUPUS, 2013, 22 (12) : 1259 - 1266
  • [32] Metabolic Syndrome and Hypogonadism
    Wespes, Eric
    EUROPEAN UROLOGY SUPPLEMENTS, 2013, 12 (02) : 2 - 6
  • [33] Migraine in Metabolic Syndrome
    Guldiken, Baburhan
    Giddiken, Sibel
    Taskiran, Bengur
    Koc, Gonul
    Turgut, Nilda
    Kabayel, Levent
    Tugrul, Armagan
    NEUROLOGIST, 2009, 15 (02) : 55 - 58
  • [34] Metabolic syndrome - Pathogenesis, medical care and dental implications
    Friedlander, Arthur H.
    Weinreb, Jane
    Friedlander, Ida
    Yagiela, John A.
    JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 2007, 138 (02) : 179 - 187
  • [35] Endothelial dysfunction in metabolic syndrome: Prevalence, pathogenesis and management
    Tziomalos, K.
    Athyros, V. G.
    Karagiannis, A.
    Mikhailidis, D. P.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2010, 20 (02) : 140 - 146
  • [36] Capsaicin in Metabolic Syndrome
    Panchal, Sunil K.
    Bliss, Edward
    Brown, Lindsay
    NUTRIENTS, 2018, 10 (05):
  • [37] Metabolic syndrome update
    Grundy, Scott M.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2016, 26 (04) : 364 - 373
  • [39] Epinephrine and the Metabolic Syndrome
    Ziegler, Michael G.
    Elayan, Hamzeh
    Milic, Milos
    Sun, Ping
    Gharaibeh, Munir
    CURRENT HYPERTENSION REPORTS, 2012, 14 (01) : 1 - 7
  • [40] Suggested involvement of ketone bodies in the pathogenesis of the metabolic syndrome
    Alexandre, Adolfo
    MEDICAL HYPOTHESES, 2013, 80 (05) : 578 - 581